Reviva Pharmaceuticals Holdings, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/47860b83-8aa6-4881-a1ee-015a5b3d962b/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-20.2M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-010126 |
| FY 2024 | $-30.8M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-010791 |
| FY 2023 | $-39.5M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-011955 |
| FY 2022 | $-28.2M | 2022-01-01 – 2022-12-31 | evidence 0001437749-24-011955 |
| FY 2021 | $-10.1M | 2021-01-01 – 2021-12-31 | evidence 0001437749-23-008502 |
| FY 2020 | $-2.4M | 2020-01-01 – 2020-12-31 | evidence 0001437749-21-006681 |
| FY 2019 | $-724.7k | 2019-03-01 – 2020-02-29 | evidence 0001104659-20-055760 |
| FY 2018 | $-152.8k | 2018-03-20 – 2019-02-28 | evidence 0001144204-19-027771 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Reviva Pharmaceuticals Holdings, Inc. — all facts · Net Income